CLINICAL_TRIALS
trial_result
· 2018-10-04
Clinical Trial Update: Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD) [Phase 2]
Summary
Phase 2 trial of orBec as monotherapy for upper GI symptoms due to chronic GVHD; study terminated with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Soligenix | Conditions: Chronic Gastrointestinal Graft vs Host Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-10-04